Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035022 · ClinicalTrials.gov registry record · Phase 1
Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas
A Phase 1 study, sponsored by BioCryst Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT00035022 is a Phase 1 study that has completed, run by BioCryst Pharmaceuticals. The registered enrollment target is 71 participants.
The verdict
NCT00035022, a Phase 1 study, has completed, sponsored by BioCryst Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.
Interventions
- DRUG BCX-1777
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2001-08 |
| Est. Completion | 2004-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035022
The ClinicalTrials.gov registry entry for NCT00035022 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioCryst Pharmaceuticals, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BCX-1777 is the first listed.
NCT00035022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00035022 about?
NCT00035022 is a clinical study titled "Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas". The purpose of this study is to determine if intravenous BCX-1777 can be given safely to improve relapsed or refractory aggressive T-cell leukemias and lymphomas.
What is the current status of trial NCT00035022?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2001-08. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00035022?
The interventions under investigation include: BCX-1777 (DRUG).
Who is sponsoring clinical trial NCT00035022?
This trial is sponsored by BioCryst Pharmaceuticals, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.